Evidence map›Paper›PMID 11383757›Full record

ArticlePharmacoEconomics2001

Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial.

M G Franzosi, M Brunetti, R Marchioli, R M Marfisi, G Tognoni, F Valagussa, GISSI-Prevenzione Investigators

Abstract read
PubMed Publisher
In one paragraph

Article in PharmacoEconomics, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 10 pooled it
9.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 10 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Guideline
  9. Pooled it
  10. Omega 3 fatty acids for prevention and treatment of cardiovascular disease.The Cochrane database of systematic reviews · 2004
    Pooled it
  11. Article
  12. Review
  13. Cardioprotective effect of indirubin in experimentally induced myocardial infarction in wistar rats.International journal of clinical and experimental pathology · 2017
    Article
  14. A Comparative Overview of Prescription Omega-3 Fatty Acid Products.P & T : a peer-reviewed journal for formulary management · 2015
    Article
  15. Overview of omega-3 Fatty Acid therapies.P & T : a peer-reviewed journal for formulary management · 2013
    Article
  16. Article
  17. Article
  18. Cost effectiveness of natural health products: a systematic review of randomized clinical trials.Evidence-based complementary and alternative medicine : eCAM · 2009
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

M G FranzosiDepartment of Cardiovascular Research, Istituto di Richerche Farmacologiche Mario Negri, Milano, Italy. franzosi@marionegri.it
M Brunetti
R Marchioli
R M Marfisi
G Tognoni
F Valagussa
GISSI-Prevenzione Investigators
Mario Negri Institute for Pharmacological Research · ITMario Negri Sud Foundation · ITAzienda Ospedaliera San Gerardo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo estimate the cost effectiveness of treatment with n-3 polyunsaturated fatty acids (PUFA) for secondary prevention after myocardial infarction (MI). DESIGN AND

settingThe cost-effectiveness analysis of n-3 PUFA treatment after MI was based on morbidity and mortality data and the use of resources obtained prospectively during the 3.5 year follow-up period of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione study. The cost-effectiveness analysis took into account the incremental number of life-years gained and the incremental costs for hospital admissions, diagnostic tests and drugs, applying a 5% discount rate. The value for money of n-3 PUFA treatment was assessed using the cost-effectiveness ratio and the number needed to treat (NNT) approach. PERSPECTIVE: Third-party payer. MAIN OUTCOME MEASURES AND

resultsThe incremental cost-effectiveness ratio for n-3 PUFA in the basecase scenario was 24,603 euro (EUR, 1999 values) per life-year gained (95% confidence interval: 22,646 to 26,930). Sensitivity analysis included the analysis of extremes, producing estimates varying from EUR15,721 to EUR52,524 per life-year gained. 172 patients would need to be treated per year with n-3 PUFA, at an annual cost of EUR68,000, in order to save 1 patient. This is comparable with the NNT value, and associated annual cost for simvastatin, but less costly than that for pravastatin.

conclusionsThe cost effectiveness of long term treatment with n-3 PUFA is comparable with other drugs recently introduced in the routine care of secondary prevention after MI. Since the clinical benefit provided by n-3 PUFA is additive, this therapy should be added to the established routine practice, with additive costs.

Indexed as

Cost-Benefit AnalysisEconomics, PharmaceuticalFatty Acids, Omega-3HumansInsurance, Health, ReimbursementItalyMyocardial InfarctionProspective StudiesFatty Acids, Omega-3

Identifiers

PMID11383757
OpenAlexW2012902436

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.